Apricus Biosciences Announces Corporate Update and First Quarter 2017 Financial Results Conference Call
May 04, 2017 06:45 ET
|
Apricus Biosciences
SAN DIEGO, May 04, 2017 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that...
Apricus Biosciences Regains Compliance with Nasdaq Continued Listing Requirements
May 02, 2017 16:05 ET
|
Apricus Biosciences
SAN DIEGO, May 02, 2017 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that on...
Apricus Biosciences Announces Pricing of $7.0 Million Public Offering
April 21, 2017 06:00 ET
|
Apricus Biosciences
SAN DIEGO, April 21, 2017 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced the...
Apricus Biosciences Provides Corporate Update, Fourth Quarter and Full Year 2016 Financial Results
March 13, 2017 16:12 ET
|
Apricus Biosciences
Sale of Ex-U.S. Vitaros Assets and Rights to Ferring Pharmaceuticals Strengthens Financial Position Vitaros U.S. NDA Re-Submission on Track for Third Quarter 2017 Conference Call / Webcast Today,...
Apricus Biosciences Announces Corporate Update, Fourth Quarter and Full Year 2016 Financial Results Conference Call
March 09, 2017 07:00 ET
|
Apricus Biosciences
SAN DIEGO, March 09, 2017 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that...
Apricus Biosciences Announces Sale of Ex-U.S. Vitaros Assets and Rights to Ferring Pharmaceuticals
March 08, 2017 16:01 ET
|
Apricus Biosciences
Apricus Expects to Receive Approximately $12.7 Million from Ferring Apricus to Focus on Vitaros U.S. NDA Re-Submission and Pipeline Assets Post-ClosingSAN DIEGO, March 08, 2017 (GLOBE NEWSWIRE) --...
Apricus Biosciences Receives Positive Nasdaq Listing Determination
February 09, 2017 06:00 ET
|
Apricus Biosciences
SAN DIEGO, Feb. 09, 2017 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that on...
Apricus Biosciences to Present at the 19th Annual BIO CEO & Investor Conference
February 08, 2017 07:00 ET
|
Apricus Biosciences
SAN DIEGO, Feb. 08, 2017 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that...
Apricus Biosciences Announces Approval of Vitaros® for the Treatment of Erectile Dysfunction in Mexico
January 18, 2017 07:00 ET
|
Apricus Biosciences
SAN DIEGO, Jan. 18, 2017 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that...
Apricus Biosciences Promotes Mary Naggs to Vice President, General Counsel
January 03, 2017 07:00 ET
|
Apricus Biosciences
SAN DIEGO, Jan. 03, 2017 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that...